Viking Therapeutics (NASDAQ: VKTX) is positioning itself as a challenger in the obesity drug market, competing directly against industry titans Eli Lilly and Novo Nordisk.
Both Eli Lilly and Novo Nordisk have generated enormous revenues from their respective weight-loss medicines, setting a high commercial bar for any new entrant.
Viking’s lead drug candidate, VK2735, has demonstrated meaningful weight reduction results in mid-stage clinical trials, offering early promise for the company.
However, positive clinical data alone does not guarantee commercial success, and the path from trial results to meaningful market share remains uncertain.
Goldman Sachs estimates the weight loss drugs market could be worth approximately $95 billion by 2030, reflecting the explosive growth trajectory of the sector.
J.P. Morgan places the broader GLP-1 market, which encompasses diabetes treatments alongside obesity drugs, at nearly $200 billion by the same year.
Using a midpoint figure of roughly $150 billion provides a useful baseline for evaluating what Viking could realistically capture if VK2735 reaches approval.
Viking could potentially have a medicine on the market within two years, putting the company on a timeline that would position it ahead of the 2030 window.
To gain traction, any approved Viking treatment would need to compete directly against two of the most well-resourced pharmaceutical companies in the world.
The obesity drug space remains one of the most commercially attractive in modern medicine, but it is also among the most fiercely contested by established players.
For investors weighing exposure to Viking, the central question is how much of that projected $150 billion market the company could credibly claim if clinical and regulatory milestones are met.
The downside scenario is equally significant, as a stumble in late-stage trials or a failed regulatory bid could erase a substantial portion of any invested capital before 2030.
